Sunday, January 16 | Overview:
Dr. Ben-Joseph, Managing Director at Outcome Capital, provides entrepreneurs with a perspective on common pitfalls and misconceptions in the management and development of life science companies. For more information, please contact |
Macroeconomic uncertainty, confusion surrounding the diagnostic regulatory landscape, and the continuing post-COVID-19 pandemic hangover have all contributed to a stagnant, quiet period for mergers and acquisitions in the in vitro diagnostics space in the first half of 2024.
Read MoreOutcome Capital Life Science Market Pulse June 2024 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?